Aquestive Therapeutics
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
30 Technology Dr, Warren, New Jersey, 07...Phone Number
(908) 941-1900Website
www.aquestive.comRevenue
$44.5 MillionStock Symbol
AQSTIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About Aquestive Therapeutics
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel product candidate for possible various dermatology conditions.Explore more
Aquestive Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aquestive Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Aquestive Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Aquestive Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Aquestive Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Aquestive Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Aquestive Therapeutics
Product Launch: Get notified when Aquestive Therapeutics launches new products
Check out if Aquestive Therapeutics is spiking on competitors!
Check if Aquestive Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Aquestive Therapeutics
Find 2 more new buyers
Compare Similar Companies to Aquestive Therapeutics
Compare insights from companies similar to Aquestive Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aquestive Therapeutics
$44.5M
51-200
Public
$217.5M
2004
Ernie TothNasdaq Aqst Oral Epinephrine Senior VP & Chief Financial Officer
Company Profile Activity
Activity Insights
Aquestive Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aquestive Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aquestive Therapeutics.
Aquestive Therapeutics financials insights
Gather financial insights about Aquestive Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Other Financing Round
$2.5M
Other Financing Round
$20M
2016
Debt
$50M
2019
Debt
$70M
2025
Other Financing Round
$75M
Aquestive Therapeutics Tech Stack
A closer look at the technologies used by Aquestive Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Finance, Financing & Debt
Person-Based
Earnings, Finance
Person-Based
Earnings, Pharmaceuticals, Finance
Event
Product Marketing, Events, Sales, Safety, Public Health, Field /Outside Sales, Field Marketing, Health & Safety, Healthcare Operations, Operations, Patient Experience
Hiring Plans
Hiring Plans
Aquestive Therapeutics News & Media
Aquestive Therapeutics Q1 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter of 2026, while reporting higher first-quarter revenue and a narrower net loss. On the company’s first-Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic business update.Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the refinancing of its existing debt facility with a new $150 million debt facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”).Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2026 and provide an update on recent developments in its business after market close on Wednesday, May 13, 2026.
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Aquestive Therapeutics
Sign Up For FreeTo access detailed company insights
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four comme... Read More
